Bremer Bank National Association Takes Position in Zoetis Inc. (NYSE:ZTS)

Bremer Bank National Association purchased a new position in shares of Zoetis Inc. (NYSE:ZTS - Free Report) during the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 32,120 shares of the company's stock, valued at approximately $5,289,000.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Atlantic Edge Private Wealth Management LLC increased its stake in Zoetis by 482.8% in the fourth quarter. Atlantic Edge Private Wealth Management LLC now owns 169 shares of the company's stock valued at $28,000 after acquiring an additional 140 shares during the period. Rakuten Securities Inc. boosted its holdings in Zoetis by 5,533.3% during the fourth quarter. Rakuten Securities Inc. now owns 169 shares of the company's stock valued at $28,000 after purchasing an additional 166 shares in the last quarter. Navigoe LLC bought a new stake in shares of Zoetis in the 4th quarter valued at approximately $30,000. Murphy & Mullick Capital Management Corp acquired a new position in shares of Zoetis in the 4th quarter worth approximately $44,000. Finally, Asset Planning Inc bought a new position in shares of Zoetis during the 4th quarter worth approximately $58,000. Institutional investors own 92.80% of the company's stock.

Insider Buying and Selling at Zoetis

In related news, EVP Roxanne Lagano sold 326 shares of Zoetis stock in a transaction that occurred on Monday, March 10th. The shares were sold at an average price of $170.00, for a total transaction of $55,420.00. Following the transaction, the executive vice president now owns 15,781 shares of the company's stock, valued at $2,682,770. This trade represents a 2.02% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Willie M. Reed sold 1,210 shares of Zoetis stock in a transaction on Tuesday, March 11th. The stock was sold at an average price of $166.14, for a total transaction of $201,029.40. Following the transaction, the director now directly owns 11,245 shares in the company, valued at approximately $1,868,244.30. This represents a 9.71% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 2,188 shares of company stock valued at $367,289. 0.18% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

Several research analysts have issued reports on the company. Stifel Nicolaus dropped their price objective on Zoetis from $180.00 to $165.00 and set a "buy" rating for the company in a research note on Monday, April 14th. Piper Sandler lifted their price target on shares of Zoetis from $205.00 to $210.00 and gave the company an "overweight" rating in a report on Monday, May 12th. Morgan Stanley reduced their price target on shares of Zoetis from $243.00 to $238.00 and set an "overweight" rating on the stock in a research report on Friday, February 14th. UBS Group dropped their price objective on shares of Zoetis from $189.00 to $170.00 and set a "neutral" rating for the company in a report on Wednesday, May 7th. Finally, Wall Street Zen raised Zoetis from a "hold" rating to a "buy" rating in a report on Friday, March 7th. One equities research analyst has rated the stock with a hold rating, eight have given a buy rating and two have issued a strong buy rating to the stock. Based on data from MarketBeat.com, Zoetis presently has a consensus rating of "Buy" and a consensus price target of $212.75.

Zoetis Trading Down 1.0%

Zoetis stock traded down $1.63 during mid-day trading on Wednesday, hitting $168.67. The stock had a trading volume of 3,086,400 shares, compared to its average volume of 2,533,370. The stock has a 50-day simple moving average of $157.04 and a two-hundred day simple moving average of $164.43. The company has a current ratio of 1.75, a quick ratio of 1.08 and a debt-to-equity ratio of 1.09. The stock has a market capitalization of $75.09 billion, a PE ratio of 30.84, a P/E/G ratio of 2.78 and a beta of 0.94. Zoetis Inc. has a 12 month low of $139.70 and a 12 month high of $200.33.

Zoetis (NYSE:ZTS - Get Free Report) last issued its quarterly earnings results on Tuesday, May 6th. The company reported $1.48 EPS for the quarter, topping the consensus estimate of $1.40 by $0.08. Zoetis had a net margin of 26.86% and a return on equity of 53.82%. The company had revenue of $2.22 billion during the quarter, compared to analysts' expectations of $2.20 billion. During the same quarter in the previous year, the company earned $1.38 EPS. Zoetis's revenue was up 1.4% on a year-over-year basis. As a group, sell-side analysts forecast that Zoetis Inc. will post 6.07 EPS for the current year.

Zoetis Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, September 3rd. Investors of record on Friday, July 18th will be paid a dividend of $0.50 per share. The ex-dividend date of this dividend is Friday, July 18th. This represents a $2.00 dividend on an annualized basis and a dividend yield of 1.19%. Zoetis's dividend payout ratio (DPR) is presently 35.91%.

About Zoetis

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.